Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial
Tamara Oser, MD, Professor of Family Medicine, Founder and Director of the Primary Care Diabetes Lab (PCDL), and Associate Director of the Practice Innovation Program, is one of the authors of the JAMA Network article "Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial," published on February 14.
When asked about the project, Dr. Oser shared that "The PCDL is proud to have been the only primary care site in the SECURE-T2D trial which led to the Omnipod 5 being the first automated insulin delivery system cleared for type 2 diabetes in the United States. Given that 90% of people with type 2 diabetes are managed in primary care settings, it is crucial to have primary care involved in studies to assure that results are scalable."
PCDL consists of a team of researchers who are dedicated to partnering with people living with diabetes, as well as primary care practices, to improve the health of those living with diabetes. The lab is a multi-disciplinary group, comprised of people living with diabetes, primary care physicians, researchers, certified diabetes care and education specialists, and pharmacists.
